Articles tagged "Induction therapy"

2019 American Transplant Congress
Induction Immunosuppression Practices in Liver Transplantation are Variable and Predict Post-Transplant Survival
T. Bittermann¹, R. Hubbard², J. Lewis¹, D. Goldberg¹
¹Gastroenterology, University of Pennsylvania, Philadelphia, PA, ²University of Pennsylvania, Philadelphia, PA
*Purpose: Unlike in other solid organ transplants, the benefits of induction immunosuppression prior to liver transplantation (LT) remain uncertain. The objective of this study was…
2019 American Transplant Congress
Hope in Action: A Multicenter Prospective Study of HIV to HIV Kidney Transplantation
C. Durand¹, S. Huprikar², M. Bowring³, D. Brown¹, B. Haydel⁴, N. Desai³, F. Naqvi¹, R. Friedman-Moraco⁵, N. Turgeon⁶, V. Stosor⁷, J. Charette⁷, S. Mehta⁸, J. Husson⁹, A. Gilbert¹⁰, M. Cooper¹¹, C. Butkus-Small¹², G. Gupta¹³, S. Mehta¹⁴, O. Adebiyi¹⁵, P. Chin-Hong¹⁶, P. Stock¹⁷, A. Massie³, S. Florman⁴, D. Segev³
¹Medicine, Johns Hopkins University, Baltimore, MD, ²Medicine, Mount Sinai, New York, NY, ³Surgery, Johns Hopkins University, Baltimore, MD, ⁴Surgery, Mount Sinai, New York, NY, ⁵Medicine, Emory University, Atlanta, GA, ⁶Surgery, Emory University, Atlanta, GA, ⁷Medicine, Northwestern University, Chicago, IL, ⁸Medicine, University of Alabama, Birmingham, AL, ⁹Medicine, University of Maryland, Baltimore, MD, ¹⁰Medicine, Georgetown University, Washington DC, DC, ¹¹Department of Surgery, Georgetown University, Washington DC, DC, ¹²Medicine, Cornell University, New York, NY, ¹³Medicine, Virginia Commonwealth University, Richmond, VA, ¹⁴Medicine, New York University, New York, NY, ¹⁵Medicine, Indiana University, Indianapolis, IN, ¹⁶Medicine, University of California at San Francisco, San Francisco, CA, ¹⁷Surgery, University of California at San Francisco, San Francisco, CA
*Purpose:HIV+ donor to HIV+ recipient (HIV D+/R+) kidney transplantation (KT) has had success in South Africa. Expansion of this practice in the US setting of…
2019 American Transplant Congress
Early Rejection Outcomes with IL-2 vs. ATG Induction among Kidney Transplant Recipients Induction Differences with Early Steroid Withdrawal
C. Burelli, A. Szczepanik, K. Yadav, E. Sanchez, M. Debroy, V. Humphreville, J. Rabets, A. Padiyar, N. Sarabu, A. Jittirat, A. Palanisamy, K. Chavin
University Hospitals Cleveland Medical Center, Cleveland, OH
*Purpose: Early steroid withdrawal in kidney transplant (Ktx) patients is controversial and has demonstrated an increased risk of acute rejection with similar long-term outcomes. Data…
2019 American Transplant Congress
Basiliximab vs. Low-Dose Thymoglobulin Induction Therapy in Low Risk Kidney Transplant Patients: Prospective Randomized Study in Southeastern Mexico
G. Martinez-Mier, P. I. Moreno-Ley, L. F. Budar-Fernandez, M. T. Mendez-Lopez, D. A. Barrera-Amoros, M. De la Paz-Roman, L. A. Jimenez-López, E. G. Aguilar-Sandoval, C. A. Allende-Castellanos
Organ Transplantation & Research, IMSS UMAE HE 14, Veracruz, Mexico
*Purpose: Demonstrate that low dose Thymoglobulin (3 mg/kg total ) has similar efficacy (DGF, SGF, BPAR, hospitalizations, adverse events, graft loss and death) than Basiliximab…
2019 American Transplant Congress
Thymoglobulin Efficacy: The Role of Dosing on Viral Infection and Rejection in Pancreas Transplantation
H. Sarumi, B. Johnson, S. Jackson, S. Hogan, J. Fisher, S. Riad, R. Kandaswamy, T. Pruett
Transplant Surgery, University of Minnesota Medical Center, Minneapolis, MN
*Purpose: While T-cell depletion therapy is standard practice for induction in pancreas transplantation, little data exists to help determine dosing and its impact on efficacy…
2019 American Transplant Congress
Predictors and Outcomes of Acute Graft-versus-Host Disease after Liver Transplant
A. Caines¹, S. Nagai², R. Salgia¹
¹Gastroenterology and Hepatology, Henry Ford Health System, Detroit, MI, ²Transplant Surgery, Henry Ford Health System, Detroit, MI
*Purpose: Graft-versus-Host Disease (GVHD) is a rare complication of liver transplant (LT) that has an estimated incidence of 0.1%-2% per year and is associated with…
2019 American Transplant Congress
Infective Complications after Renal Transplantation – A Single Centre Experience Comparing Alemtuzumab to Basiliximab Induction
R. Czajka, M. Welberry Smith, M. Gittus, E. Lindley, M. Vernon
Renal Medicine, St James' University Hospital, Leeds, United Kingdom
*Purpose: Our centre predominantly uses alemtuzumab as induction immunosuppression for renal transplantation. We examined infective complications after renal transplantation, comparing different induction, and maintenance, immunosuppression…
2019 American Transplant Congress
Type of Induction Does Not Impact Patient or Kidney Allograft Survival in Simultaneous Liver and Kidney Transplant Recipients in the United States
S. Riad¹, N. Lim², S. Jackson³, J. Lake²
¹University of Minnesota, Minneapolis, MN, ²Medicine, University of Minnesota, Minneapolis, MN, ³Complex Care Analytics, Fairview Health Services, Minneapolis, MN
*Purpose: Induction practices vary widely in the United States for patients undergoing simultaneous liver and kidney (SLK) transplantation. We examined the impact of induction type…
2019 American Transplant Congress
ECDI-Treated Donor Leukocytes in Primate Cardiac Allograft Recipients
Z. Alikhassy Habibabady¹, T. Zhang², W. Sun², X. Cheng², L. Burdorf¹, I. Tatarov², S. Sendil², I. Behroozfard², B. Cerel¹, D. Parsell², R. N. Pierson III¹, X. Luo³, A. M. Azimzadeh¹
¹Surgery, Massachusetts General Hospital and Harvard School of Medicine, Boston, MA, ²Surgery, University of Maryland School of Medicine, Baltimore, MD, ³Duke Transplant Center, Duke University, Durham, NC
*Purpose: Ethyl carbodiimide (ECDI)-fixed donor leukocytes exhibit tolerogenic immunomodulation in murine models of autoimmunity and transplantation, and nonhuman primate islet transplantation. Here in pilot studies…
2019 American Transplant Congress
A Prospective Randomized Multicenter Trial (B E S T Trial) of Belatacept-Based C N I- and Corticosteroid-Free Immunosuppression: Final Two Year Results
D. B. Kaufman¹, A. R. Shields², J. P. Leone³, A. Wiseman⁴, A. J. Matas⁵, P. West-Thielke⁶, J. Lipscomb², E. King², R. R. Alloway⁷, E. S. Woodle for the BEST Study Group²
¹University of Wisconsin, Madison, WI, ²University of Cincinnati, Cincinnati, OH, ³Tampa General, Tampa, FL, ⁴University of Colorado School of Medicine, Denver, CO, ⁵University of Minnesota, Minneapolis, MN, ⁶University of Illinois, Chicago, Chicago, IL, ⁷University of Cincinnati, Cincinnati, WI
*Purpose: The BEST Trial (Belatacept-based Early Steroid Withdrawal Trial) is a prospective, randomized, multi-center trial designed to compare two belatacept (BELA)-based calcineurin inhibitor-free (CNI), early…

« Previous Page
1
…
8
9
10
11
12
…
31
Next Page »